0 false false false false false false false false false false true false false false false false false No description of principal activity 2023-09-01 Sage Accounts Production Advanced 2024 - FRS102_2024 xbrli:pure xbrli:shares iso4217:GBP 13559381 2023-09-01 2024-08-31 13559381 2024-08-31 13559381 2023-08-31 13559381 2022-09-01 2023-08-31 13559381 2023-08-31 13559381 2022-08-31 13559381 bus:Director1 2023-09-01 2024-08-31 13559381 core:WithinOneYear 2024-08-31 13559381 core:WithinOneYear 2023-08-31 13559381 core:ShareCapital 2024-08-31 13559381 core:ShareCapital 2023-08-31 13559381 core:RetainedEarningsAccumulatedLosses 2024-08-31 13559381 core:RetainedEarningsAccumulatedLosses 2023-08-31 13559381 bus:SmallEntities 2023-09-01 2024-08-31 13559381 bus:AuditExemptWithAccountantsReport 2023-09-01 2024-08-31 13559381 bus:SmallCompaniesRegimeForAccounts 2023-09-01 2024-08-31 13559381 bus:PrivateLimitedCompanyLtd 2023-09-01 2024-08-31 13559381 bus:FullAccounts 2023-09-01 2024-08-31
COMPANY REGISTRATION NUMBER: 13559381
Dermavival Clinic Limited
Filleted Unaudited Financial Statements
31 August 2024
Dermavival Clinic Limited
Statement of Financial Position
31 August 2024
2024
2023
Note
£
£
£
Creditors: amounts falling due within one year
4
1,482
725
-------
----
Net current liabilities
1,482
725
-------
----
Total assets less current liabilities
( 1,482)
( 725)
-------
----
Capital and reserves
Called up share capital
1
1
Profit and loss account
( 1,483)
( 726)
-------
----
Shareholders deficit
( 1,482)
( 725)
-------
----
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
For the year ending 31 August 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;
- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .
These financial statements were approved by the board of directors and authorised for issue on 27 May 2025 , and are signed on behalf of the board by:
Mrs Z Morritt
Director
Company registration number: 13559381
Dermavival Clinic Limited
Notes to the Financial Statements
Year ended 31 August 2024
1. General information
The company is a private company limited by shares, registered in England and Wales. The address of the registered office is Lyndhurst, 1 Cranmer Street, Long Eaton, Nottingham, NG10 1NJ.
2. Statement of compliance
These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis. The financial statements are prepared in sterling, which is the functional currency of the entity.
Going concern
In accordance with her responsibilities the director has considered the appropriateness of the going concern basis for the preparation of the financial statements. In forming her view, she has considered a period of at least 12 months from the date of approval of the financial statements. The company has a deficiency of assets as at 31 August 2024. It depends on the support of the director. The director considers it appropriate to prepare the financial statements on a going concern basis.
Revenue recognition
Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for services rendered.
Financial instruments
A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost.
4. Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans and overdrafts
20
48
Other creditors
1,462
677
-------
----
1,482
725
-------
----
5. Director's advances, credits and guarantees
Amounts owed to the director at the year end was £1,462 (2023: £677). The director's loan is interest free and repayable on demand.